New Thematic Series
Recent Advances in Pulmonary Hypertension
Pulmonary hypertension is associated with a high degree of morbidity and mortality in patients with World Health Organization Group 1 pulmonary hypertension (pulmonary artery hypertension) as well as Groups 2 to 5 pulmonary hypertension (pulmonary hypertension attributable to left heart disease, lung disease, thromboembolic disease, and miscellaneous causes, respectively). Historically, the underlying cause of pulmonary hypertension coupled with a defining hemodynamic profile has been used for the clinical classification of patients into different groups, in part, to facilitate management. Over the past several years, advances in the field have increased our understanding of the pathobiology, clinical course, and treatment outcomes for patients with pulmonary hypertension. Along these lines, recent findings from randomized, clinical trials have demonstrated efficacy of novel therapeutics and expanded treatment options for this important cardiopulmonary disease.
In this thematic series in Circulation on Recent Advances in Pulmonary Hypertension, a group of experts will discuss progress in the field and remaining controversies that are likely to have broad applicability to patients with different forms of pulmonary hypertension. The topics reviewed will cover practical considerations in the care of patients with pulmonary hypertension, such as clinical diagnosis, therapeutic interventions, use of noninvasive imaging to evaluate pulmonary vascular-right ventricular function, and the role of mechanical support for the failing right ventricle. Next, select populations of patients with pulmonary hypertension who clinicians may encounter in practice will be discussed, including patients with congenital heart disease, human immunodeficiency virus, or those who develop pulmonary hypertension as a consequence of exposure to high altitude. The series will also provide a focused review of current end points used in clinical trials and their attendant limitations as a consideration for how to interpret findings from previous studies as well as design future trials in this field. Finally, recent translational advances with clinical implications for patients with pulmonary hypertension in the areas of cellular metabolism, neurohumoral signaling, and sex hormones will be reviewed. Together, the reviews in this series aim to provide the reader with a state-of-the art view of diagnostic modalities and therapeutic interventions as well as an introduction to new frontiers in the care of patients afflicted with this heterogeneous and complex disease.
- © 2014 American Heart Association, Inc.